Immuneering Corp (IMRX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Immuneering Corp.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 5 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 314.6% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.25 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.28 | – | 1 | – | -2,486.40 | -15 | -15 |
| 2025: Q1 | -0.23 | – | 0 | – | – | -14 | -14 |
| 2025: Q2 | -0.22 | – | 0 | – | – | -9 | -9 |
| 2025: Q3 | -0.23 | – | 0 | – | – | -12 | -12 |
| 2025: Q4 | -0.18 | – | 0 | -100.00 | – | -10 | -10 |
| 2026: Q1 | -0.21 | – | 0 | – | – | -18 | -19 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Immuneering Corporation, ein onkologisches Unternehmen in der Spätphase, entwickelt Medikamente für breite Krebspatientenpopulationen in den USA. Das Unternehmen entwickelt IMM-1-104 (Atebimetinib), einen dualen MEK-Inhibitor, der sich in einer klinischen Phase-3-Studie zur Behandlung von Krebspatienten, darunter Bauchspeicheldrüse…
| Employees | 55 |
|---|---|
| Headquarters | Cambridge, MA |
| Website | immuneering.com |
| IPO Date | 30. Jul 2021 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, CEO & Director | 1983 |
| Robert J. Carpenter M.B.A., M.S. | Co-Founder & Chair Emeritus | 1946 |
| Brett M. Hall Ph.D. | Chief Scientific Officer | 1969 |
| Michael D. Bookman J.D. | Chief Legal Officer & Secretary | 1987 |
| Mallory Morales CPA | Senior VP of Finance, Chief Accounting Officer & Treasurer | 1984 |
| Paula George CPA | Director of Accounting & Operations and Assistant Corporate Controller | – |
| Courtney Dugan | VP and Head of Investor Relations & Corporate Communications | – |
| Leah R. Neufeld | Chief People Officer | 1972 |
| Peter King Ph.D. | Head of Discovery & VP | – |
| Praveen Nair Ph.D. | Head of Translational Pharmacology & VP | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.